308 related articles for article (PubMed ID: 28049532)
41. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
[TBL] [Abstract][Full Text] [Related]
42. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
[TBL] [Abstract][Full Text] [Related]
43. Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Nieto-Jimenez C; Alcaraz-Sanabria A; Martinez-Canales S; Corrales-Sanchez V; Montero JC; Burgos M; Nuncia-Cantarero M; Pandiella A; Galan-Moya EM; Ocaña A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261142
[TBL] [Abstract][Full Text] [Related]
44. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
45. Involvement of p38 mitogen-activated protein kinase in acquired gemcitabine-resistant human urothelial carcinoma sublines.
Kao YT; Hsu WC; Hu HT; Hsu SH; Lin CS; Chiu CC; Lu CY; Hour TC; Pu YS; Huang AM
Kaohsiung J Med Sci; 2014 Jul; 30(7):323-30. PubMed ID: 24924837
[TBL] [Abstract][Full Text] [Related]
46. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death.
Del Nagro CJ; Choi J; Xiao Y; Rangell L; Mohan S; Pandita A; Zha J; Jackson PK; O'Brien T
Cell Cycle; 2014; 13(2):303-14. PubMed ID: 24247149
[TBL] [Abstract][Full Text] [Related]
47. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
48. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
49. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.
Morgan MA; Parsels LA; Parsels JD; Mesiwala AK; Maybaum J; Lawrence TS
Cancer Res; 2005 Aug; 65(15):6835-42. PubMed ID: 16061666
[TBL] [Abstract][Full Text] [Related]
50. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.
Morgan MA; Parsels LA; Parsels JD; Lawrence TS; Maybaum J
Cell Cycle; 2006 Sep; 5(17):1983-8. PubMed ID: 16931916
[TBL] [Abstract][Full Text] [Related]
51. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.
Magnussen GI; Emilsen E; Giller Fleten K; Engesæter B; Nähse-Kumpf V; Fjær R; Slipicevic A; Flørenes VA
BMC Cancer; 2015 Jun; 15():462. PubMed ID: 26054341
[TBL] [Abstract][Full Text] [Related]
52. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.
Yang H; Yoon SJ; Jin J; Choi SH; Seol HJ; Lee JI; Nam DH; Yoo HY
Biochem Biophys Res Commun; 2011 Mar; 406(1):53-8. PubMed ID: 21291864
[TBL] [Abstract][Full Text] [Related]
54. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
55. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
Azorsa DO; Gonzales IM; Basu GD; Choudhary A; Arora S; Bisanz KM; Kiefer JA; Henderson MC; Trent JM; Von Hoff DD; Mousses S
J Transl Med; 2009 Jun; 7():43. PubMed ID: 19519883
[TBL] [Abstract][Full Text] [Related]
56. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Liang M; Zhao T; Ma L; Guo Y
Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
[TBL] [Abstract][Full Text] [Related]
57. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
[TBL] [Abstract][Full Text] [Related]
58. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Jeon HG; Yoon CY; Yu JH; Park MJ; Lee JE; Jeong SJ; Hong SK; Byun SS; Lee SE
J Urol; 2011 Nov; 186(5):2084-93. PubMed ID: 21944112
[TBL] [Abstract][Full Text] [Related]
59. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
60. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
